J. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary et al., One Hundred Years After ???Carcinoid???: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States, Journal of Clinical Oncology, vol.26, issue.18, pp.3063-72, 2008.
DOI : 10.1200/JCO.2007.15.4377

R. Thakker, Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4), Molecular and Cellular Endocrinology, vol.386, issue.1-2, pp.2-15, 2014.
DOI : 10.1016/j.mce.2013.08.002

R. Thakker, P. Newey, G. Walls, J. Bilezikian, H. Dralle et al., Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1), The Journal of Clinical Endocrinology & Metabolism, vol.97, issue.9, 2012.
DOI : 10.1210/jc.2012-1230

M. Lemos and R. Thakker, Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene, Human Mutation, vol.57, issue.1, 2008.
DOI : 10.1002/humu.20605

S. Guo and M. Sawicki, Molecular and Genetic Mechanisms of Tumorigenesis in Multiple Endocrine Neoplasia Type-1, Molecular Endocrinology, vol.15, issue.10, pp.1653-64, 2001.
DOI : 10.1210/mend.15.10.0717

S. Guru, P. Goldsmith, A. Burns, S. Marx, A. Spiegel et al., Menin, the product of the MEN1 gene, is a nuclear protein, Proceedings of the National Academy of Sciences, vol.95, issue.4, pp.1630-1634, 1998.
DOI : 10.1073/pnas.95.4.1630

S. Agarwal, S. Guru, C. Heppner, M. Erdos, R. Collins et al., Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell, pp.143-52, 1999.

C. Heppner, K. Bilimoria, S. Agarwal, M. Kester, L. Whitty et al., The tumor suppressor protein menin interacts with NF-??B proteins and inhibits NF-??B-mediated transactivation, Oncogene, vol.20, issue.36, pp.4917-4942, 2001.
DOI : 10.1038/sj.onc.1204529

H. Kaji, L. Canaff, J. Lebrun, D. Goltzman, and G. Hendy, Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type ?? signaling, Proceedings of the National Academy of Sciences, vol.98, issue.7, pp.3837-3879, 2001.
DOI : 10.1073/pnas.061358098

P. La, Y. Yang, S. Karnik, A. Silva, R. Schnepp et al., Menin-mediated Caspase 8 Expression in Suppressing Multiple Endocrine Neoplasia Type 1, Journal of Biological Chemistry, vol.282, issue.43, pp.31332-31372, 2007.
DOI : 10.1074/jbc.M609555200

C. Hughes, O. Rozenblatt-rosen, T. Milne, T. Copeland, S. Levine et al., Menin Associates with a Trithorax Family Histone Methyltransferase Complex and with the Hoxc8 Locus, Molecular Cell, vol.13, issue.4, pp.587-97, 2004.
DOI : 10.1016/S1097-2765(04)00081-4

P. Schwartz and C. Guillot-tantay, Santé publique médecine légale, médecine du travail. Paris: Éd. Vernazobres-Grego, 2012.

B. Harding, M. Lemos, A. Reed, G. Walls, J. Jeyabalan et al., Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia, Endocrine Related Cancer, vol.16, issue.4, pp.1313-1340, 2009.
DOI : 10.1677/ERC-09-0082

S. Agarwal, Exploring the tumors of multiple endocrine neoplasia type 1 in mouse models for basic and preclinical studies, International Journal of Endocrine Oncology, vol.1, issue.2, pp.153-61, 2014.
DOI : 10.2217/ije.14.16

A. Wimmel, B. Wiedenmann, and S. Rosewicz, Autocrine growth inhibition by transforming growth factor ??-1 (TGF??-1) in human neuroendocrine tumour cells, Gut, vol.52, issue.9, pp.1308-1324, 2003.
DOI : 10.1136/gut.52.9.1308

H. Sowa, H. Kaji, R. Kitazawa, S. Kitazawa, T. Tsukamoto et al., Menin inactivation leads to loss of transforming growth factor beta inhibition of parathyroid cell proliferation and parathyroid hormone secretion. Cancer Res, pp.2222-2230, 2004.

J. Lebrun and . Activin, Activin, TGF-?? and Menin in Pituitary Tumorigenesis, Adv Exp Med Biol, vol.668, pp.69-78, 2009.
DOI : 10.1007/978-1-4419-1664-8_7

M. Anlauf, A. Perren, C. Meyer, S. Schmid, P. Saremaslani et al., Precursor Lesions in Patients With Multiple Endocrine Neoplasia Type 1--Associated Duodenal Gastrinomas, Gastroenterology, vol.128, issue.5, pp.1187-98, 2005.
DOI : 10.1053/j.gastro.2005.01.058

C. Biondi, M. Gartside, P. Waring, K. Loffler, M. Stark et al., Conditional Inactivation of the Men1 Gene Leads to Pancreatic and Pituitary Tumorigenesis but Does Not Affect Normal Development of These Tissues, Molecular and Cellular Biology, vol.24, issue.8, pp.3125-3156, 2004.
DOI : 10.1128/MCB.24.8.3125-3131.2004

C. Pieterman, E. Conemans, K. Dreijerink, J. De-laat, H. Timmers et al., Thoracic and duodenopancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1: natural history and function of menin in tumorigenesis, Endocrine Related Cancer, vol.21, issue.3, 2014.
DOI : 10.1530/ERC-13-0482

A. Machens, L. Schaaf, W. Karges, K. Frank-raue, D. Bartsch et al., Age-related penetrance of endocrine tumours in multiple endocrine neoplasia type 1 (MEN1): a multicentre study of 258 gene carriers, Clinical Endocrinology, vol.243, issue.0, pp.613-635, 2007.
DOI : 10.1210/jc.86.12.5658

P. Goudet, A. Murat, C. Binquet, C. Cardot-bauters, A. Costa et al., Risk Factors and Causes of Death in MEN1 Disease. A GTE (Groupe d???Etude des Tumeurs Endocrines) Cohort Study Among 758 Patients, World Journal of Surgery, vol.228, issue.2, pp.249-55, 2010.
DOI : 10.1007/s00268-009-0290-1

A. Andrew, B. Kramer, and B. Rawdon, The origin of gut and pancreatic neuroendocrine (APUD) cells???the last word?, The Journal of Pathology, vol.387, issue.2, pp.117-125, 1998.
DOI : 10.1002/(SICI)1096-9896(1998100)186:2<117::AID-PATH152>3.0.CO;2-J

L. Douarin, N. Teillet, M. Couly, and G. , Chimères embryonnaires et développement du système nerveux. médecine/sciences, p.228, 1990.

E. Williams and M. Sandler, The classification of carcinoid tumours. Lancet, Feb, vol.21, issue.7275, pp.238-247, 1963.

I. Modlin, K. Lye, and M. Kidd, A 5-decade analysis of 13,715 carcinoid tumors. Cancer, pp.934-59, 2003.

C. Lepage, A. Bouvier, J. Phelip, C. Hatem, C. Vernet et al., Incidence and management of malignant digestive endocrine tumours in a well defined French population, Gut, vol.53, issue.4, 2004.
DOI : 10.1136/gut.2003.026401

É. Baudin, Tumeurs endocrines thoraciques et digestives, 2008.
DOI : 10.1007/978-2-287-35574-5

R. Delellis, I. Agency, . Research, and . Cancer, World Health Organization, International Academy of Pathology, International Association for the Study of Lung Cancer, editors. Pathology and genetics of tumours of endocrine organs, 2004.

F. Bosman, World Health Organization, International Agency for Research on Cancer, editors. WHO classification of tumours of the digestive system, 2010.

G. Rindi, G. Klöppel, H. Alhman, M. Caplin, A. Couvelard et al., TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch, pp.395-401, 2006.

G. Rindi, G. Klöppel, A. Couvelard, P. Komminoth, M. Körner et al., TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system, Virchows Archiv, vol.80, issue.Suppl 4, pp.757-62, 2007.
DOI : 10.1007/s00428-007-0452-1

L. Thomas-marques, A. Murat, B. Delemer, A. Penfornis, C. Cardot-bauters et al., Prospective Endoscopic Ultrasonographic Evaluation of the Frequency of Nonfunctioning Pancreaticoduodenal Endocrine Tumors in Patients with Multiple Endocrine Neoplasia Type 1, The American Journal of Gastroenterology, vol.24, issue.1
DOI : 10.1002/bjs.4110

F. Triponez, D. Dosseh, P. Goudet, P. Cougard, C. Bauters et al., Epidemiology Data on 108 MEN 1 Patients From the GTE With Isolated Nonfunctioning Tumors of the Pancreas, Annals of Surgery, vol.243, issue.2, pp.265-72, 2006.
DOI : 10.1097/01.sla.0000197715.96762.68

R. Jensen, G. Cadiot, M. Brandi, W. De-herder, G. Kaltsas et al., ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes, Neuroendocrinology, vol.95, issue.2, pp.98-119, 2012.
DOI : 10.1159/000335591

G. Delle-fave, D. Kwekkeboom, E. Van-cutsem, G. Rindi, B. Kos-kudla et al., ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms, Neuroendocrinology, vol.95, issue.2, pp.74-87, 2012.
DOI : 10.1159/000335595

W. Travis, . World-health, and . Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and genetics of tumours of the lung, pleura, thymus, and heart, 2004.

B. Mccaughan, N. Martini, and M. Bains, Bronchial carcinoids. Review of 124 cases, J Thorac Cardiovasc Surg, vol.89, issue.1, pp.8-17, 1985.

R. Garcia-carbonero, P. Jimenez-fonseca, A. Teulé, J. Barriuso, and I. Sevilla, SEOM clinical guidelines for the diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) 2014, Clinical and Translational Oncology, vol.7, issue.2, pp.1025-1059, 2014.
DOI : 10.1007/s12094-014-1214-6

O. Toole, D. Grossman, A. Gross, D. , D. Fave et al., ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers, Neuroendocrinology, vol.90, issue.2, pp.194-202, 2009.
DOI : 10.1159/000225948

A. Phan, K. Oberg, J. Choi, L. Harrison, M. Hassan et al., NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors, Pancreas, vol.39, issue.6, 2010.
DOI : 10.1097/MPA.0b013e3181ec1380

B. Vergès, F. Boureille, P. Goudet, A. Murat, A. Beckers et al., Pituitary Disease in MEN Type 1 (MEN1): Data from the France-Belgium MEN1 Multicenter Study, Journal of Clinical Endocrinology & Metabolism, vol.87, issue.2, pp.457-65, 2002.
DOI : 10.1210/jc.87.2.457

B. Gatta-cherifi, O. Chabre, A. Murat, P. Niccoli, C. Cardot-bauters et al., Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d'etude des Tumeurs Endocrines database, European Journal of Endocrinology, vol.166, issue.2, pp.269-79
DOI : 10.1530/EJE-11-0679

B. Asgharian, Y. Chen, N. Patronas, P. Peghini, J. Reynolds et al., Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res Off J Am Assoc Cancer Res, Feb, vol.110, issue.3, pp.869-80, 2004.

S. Sadowski and F. Triponez, Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surg, Feb, vol.4, issue.1, pp.63-71, 2015.

A. Sundin, M. Vullierme, G. Kaltsas, and U. Plöckinger, ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Radiological Examinations, Mallorca Consensus Conference participants, pp.167-83, 2009.
DOI : 10.1159/000184855

D. Sahani, P. Bonaffini, ?. Fernández, C. Del-castillo, and M. Blake, Gastroenteropancreatic Neuroendocrine Tumors: Role of Imaging in Diagnosis and Management, Radiology, vol.266, issue.1, pp.38-61, 2013.
DOI : 10.1148/radiol.12112512

A. Scarsbrook, R. Thakker, J. Wass, F. Gleeson, and R. Phillips, Multiple Endocrine Neoplasia: Spectrum of Radiologic Appearances and Discussion of a Multitechnique Imaging Approach, RadioGraphics, vol.26, issue.2, pp.433-51, 2006.
DOI : 10.1148/rg.262055073

L. Bodei, A. Sundin, M. Kidd, V. Prasad, and I. Modlin, The Status of Neuroendocrine Tumor Imaging: From Darkness to Light?, Neuroendocrinology, vol.101, issue.1, pp.1-17, 2015.
DOI : 10.1159/000367850

Y. Wang, Z. Chen, V. Yaghmai, P. Nikolaidis, R. Mccarthy et al., Diffusion-weighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics, Journal of Magnetic Resonance Imaging, vol.113, issue.Suppl 1, pp.1071-1080, 2011.
DOI : 10.1002/jmri.22541

M. Anderson, S. Carpenter, N. Thompson, T. Nostrant, G. Elta et al., Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas, The American Journal of Gastroenterology, vol.111, issue.9, pp.2271-2278, 2000.
DOI : 10.1007/s002689900038

D. Stark, A. Moss, H. Goldberg, and C. Deveney, CT of pancreatic islet cell tumors. Radiology, Feb, vol.150, issue.2, pp.491-495, 1984.

P. Rossi, A. Baert, R. Passariello, G. Simonetti, P. Pavone et al., CT of functioning tumors of the pancreas, American Journal of Roentgenology, vol.144, issue.1, pp.57-60, 1985.
DOI : 10.2214/ajr.144.1.57

L. Van-hoe, S. Gryspeerdt, G. Marchal, A. Baert, and L. Mertens, Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images., American Journal of Roentgenology, vol.165, issue.6, pp.1437-1446, 1995.
DOI : 10.2214/ajr.165.6.7484581

C. Procacci, G. Carbognin, S. Accordini, C. Biasiutti, E. Bicego et al., Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization, European Radiology, vol.11, issue.7, pp.1175-83, 2001.
DOI : 10.1007/s003300000714

J. Fidler, J. Fletcher, C. Reading, J. Andrews, G. Thompson et al., Preoperative Detection of Pancreatic Insulinomas on Multiphasic Helical CT, American Journal of Roentgenology, vol.181, issue.3, 2003.
DOI : 10.2214/ajr.181.3.1810775

R. Thoeni, U. Mueller-lisse, R. Chan, N. Do, and P. Shyn, Detection of Small, Functional Islet Cell Tumors in the Pancreas: Selection of MR Imaging Sequences for Optimal Sensitivity, Radiology, vol.214, issue.2, pp.483-90, 2000.
DOI : 10.1148/radiology.214.2.r00fe32483

R. Semelka, C. Custodio, C. Balci, N. Woosley, and J. , Neuroendocrine tumors of the pancreas: Spectrum of appearances on MRI, Journal of Magnetic Resonance Imaging, vol.19, issue.2, pp.141-149, 2000.
DOI : 10.1002/(SICI)1522-2586(200002)11:2<141::AID-JMRI10>3.0.CO;2-U

C. Proye, P. Malvaux, F. Pattou, B. Filoche, J. Godchaux et al., Noninvasive imaging of insulinomas and gastrinomas with endoscopic ultrasonography and somatostatin receptor scintigraphy. Surgery, pp.1134-1177, 1998.

D. Angelis, C. Carucci, P. Repici, A. Rizzetto, and M. , Endosonography in decision making and management of gastrointestinal endocrine tumors, European Journal of Ultrasound, vol.10, issue.2-3, pp.2-3139, 1999.
DOI : 10.1016/S0929-8266(99)00054-3

A. Chiti, S. Fanti, G. Savelli, A. Romeo, B. Bellanova et al., Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.25, issue.10, pp.1396-403, 1998.
DOI : 10.1007/s002590050314

B. Kumbasar, I. Kamel, A. Tekes, J. Eng, E. Fishman et al., Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS. Abdom Imaging, pp.696-702, 2004.

A. Hubalewska-dydejczyk, K. Fröss-baron, R. Miko?ajczak, H. Maecke, B. Huszno et al., 99mTc-EDDA/HYNIC-octreotate scintigraphy, an efficient method for the detection and staging of carcinoid tumours: results of 3??years??? experience, European Journal of Nuclear Medicine and Molecular Imaging, vol.19, issue.2, 2006.
DOI : 10.1007/s00259-006-0113-7

J. Cwik?a, J. Buscombe, M. Caplin, A. Watkinson, J. Walecki et al., Diagnostic imaging of carcinoid metastases to the abdomen and pelvis, Med Sci Monit Int Med J Exp Clin Res, vol.10, pp.9-16, 2004.

B. Carlson, C. Johnson, D. Stephens, E. Ward, and L. Kvols, MRI of Pancreatic Islet Cell Carcinoma, Journal of Computer Assisted Tomography, vol.17, issue.5, pp.735-775, 1993.
DOI : 10.1097/00004728-199309000-00013

W. Shi, C. Johnston, K. Buchanan, W. Ferguson, J. Laird et al., Localization of neuroendocrine tumours with [111In] DTPA-octreotide scintigraphy (Octreoscan): a comparative study with CT and MR imaging, QJM, vol.91, issue.4, pp.295-301, 1998.
DOI : 10.1093/qjmed/91.4.295

C. Dromain, T. De-baere, J. Lumbroso, H. Caillet, A. Laplanche et al., Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging, Journal of Clinical Oncology, vol.23, issue.1, pp.70-78, 2005.
DOI : 10.1200/JCO.2005.01.013

D. Assignies, G. Fina, P. Bruno, O. Vullierme, M. Tubach et al., High Sensitivity of Diffusion-weighted MR Imaging for the Detection of Liver Metastases from Neuroendocrine Tumors: Comparison with T2-weighted and Dynamic Gadolinium-enhanced MR Imaging, Radiology, vol.268, issue.2, pp.390-399, 2013.
DOI : 10.1148/radiol.13121628

C. Barbe, A. Murat, B. Dupas, P. Ruszniewski, A. Tabarin et al., Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver, 2012.

M. Lewis, G. Thompson, and W. Young, Preoperative Assessment of the Pancreas in Multiple Endocrine Neoplasia Type 1, World Journal of Surgery, vol.19, issue.6, pp.1375-81
DOI : 10.1007/s00268-012-1539-7

S. Van-asselt, A. Brouwers, H. Van-dullemen, E. Van-der-jagt, A. Bongaerts et al., EUS is superior for detection of pancreatic lesions compared with standard imaging in patients with multiple endocrine neoplasia type 1, Gastrointestinal Endoscopy, vol.81, issue.1, pp.159-67, 2015.
DOI : 10.1016/j.gie.2014.09.037

J. Reubi, B. Waser, J. Schaer, and J. Laissue, Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands

Y. Taniyama, T. Suzuki, Y. Mikami, T. Moriya, S. Satomi et al., Systemic Distribution of Somatostatin Receptor Subtypes in Human: An Immunohistochemical Study, Endocrine Journal, vol.52, issue.5, 2005.
DOI : 10.1507/endocrj.52.605

L. Møller, C. Stidsen, B. Hartmann, and J. Holst, Somatostatin receptors, Biochimica et Biophysica Acta (BBA) - Biomembranes, vol.1616, issue.1, pp.1-84, 2003.
DOI : 10.1016/S0005-2736(03)00235-9

V. Zamora, A. Cabanne, R. Salanova, C. Bestani, E. Domenichini et al., Immunohistochemical expression of somatostatin receptors in digestive endocrine tumours. Dig Liver Dis, pp.220-225, 2010.

J. Bertherat, F. Tenenbaum, K. Perlemoine, C. Videau, J. Alberini et al., Study, The Journal of Clinical Endocrinology & Metabolism, vol.88, issue.11, pp.5353-60, 2003.
DOI : 10.1210/jc.2002-021895

URL : https://hal.archives-ouvertes.fr/hal-00625303

M. Papotti, M. Bongiovanni, M. Volante, E. Allìa, S. Landolfi et al., Expression of somatostatin receptor types 1???5 in 81 cases of gastrointestinal and pancreatic endocrine tumors, Virchows Archiv, vol.440, issue.5, pp.461-75, 2002.
DOI : 10.1007/s00428-002-0609-x

L. Righi, M. Volante, V. Tavaglione, A. Billè, L. Daniele et al., Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases, Annals of Oncology, vol.21, issue.3, pp.548-55, 2010.
DOI : 10.1093/annonc/mdp334

G. Taboada, R. Luque, W. Bastos, R. Guimarães, J. Marcondes et al., Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas, European Journal of Endocrinology, vol.156, issue.1, pp.65-74, 2007.
DOI : 10.1530/eje.1.02313

B. Mariniello, I. Finco, P. Sartorato, A. Patalano, M. Iacobone et al., Somatostatin receptor expression in adrenocortical tumors and effect of a new somatostatin analog SOM230 on hormone secretion in vitro and in ex vivo adrenal cells, Journal of Endocrinological Investigation, vol.177, issue.6, 2011.
DOI : 10.1007/BF03346721

K. Pazaitou-panayiotou, T. Janson, E. Koletsa, T. Kotoula, V. Stridsberg et al., Somatostatin receptor expression in non-medullary thyroid carcinomas. Horm Athens Greece, pp.290-296, 2012.

M. Volante, R. Rosas, E. Allìa, R. Granata, A. Baragli et al., Somatostatin, cortistatin and their receptors in tumours, Molecular and Cellular Endocrinology, vol.286, issue.1-2, pp.219-248, 2008.
DOI : 10.1016/j.mce.2007.12.002

URL : https://hal.archives-ouvertes.fr/hal-00531971

A. Zielke, C. Hasse, C. Bruns, H. Sitter, and M. Rothmund, Octreotide: Effective treatment for hyperparathyroidism? A prospective, randomized, controlled clinical trial, Surgery, vol.121, issue.6, 1997.
DOI : 10.1016/S0039-6060(97)90047-7

U. Kumar, S. Grigorakis, H. Watt, R. Sasi, L. Snell et al., Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1???5 and correlation with receptor protein expression and tumor pathology, Breast Cancer Research and Treatment, vol.49, issue.2, pp.175-86, 2005.
DOI : 10.1007/s10549-005-2414-0

C. Verhoef, H. Van-dekken, L. Hofland, P. Zondervan, J. De-wilt et al., Somatostatin Receptor in Human Hepatocellular Carcinomas: Biological, Patient and Tumor Characteristics, Digestive Surgery, vol.25, issue.1, pp.21-27, 2008.
DOI : 10.1159/000117819

N. Dizeyi, L. Konrad, A. Bjartell, H. Wu, V. Gadaleanu et al., Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines, Urologic Oncology: Seminars and Original Investigations, vol.7, issue.3, pp.91-99, 2002.
DOI : 10.1016/S1078-1439(01)00173-9

S. Laws, A. Gough, A. Evans, M. Bains, and J. Primrose, Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae, British Journal of Cancer, vol.75, issue.3, pp.360-366, 1997.
DOI : 10.1038/bjc.1997.59

A. Tsutsumi, H. Takano, K. Ichikawa, S. Kobayashi, and T. Koike, Expression of Somatostatin Receptor Subtype 2 mRNA in Human Lymphoid Cells, Cellular Immunology, vol.181, issue.1, pp.44-53, 1997.
DOI : 10.1006/cimm.1997.1193

E. Lichtenauer-kaligis, V. Dalm, S. Oomen, D. Mooij, P. Van-hagen et al., Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets, European Journal of Endocrinology, vol.150, issue.4, pp.565-77, 2004.
DOI : 10.1530/eje.0.1500565

J. Reubi, B. Waser, H. Markusse, E. Krenning, M. Vanhagen et al., Vascular somatostatin receptors in synovium from patients with rheumatoid arthritis, European Journal of Pharmacology, vol.271, issue.2-3, pp.2-3371, 1994.
DOI : 10.1016/0014-2999(94)90796-X

T. Bokum, A. Hofland, L. De-jong, G. Bouma, J. Melief et al., Immunohistochemical localization of somatostatin receptor sst2A in sarcoid granulomas, European Journal of Clinical Investigation, vol.8, issue.1, pp.630-636, 1999.
DOI : 10.1007/s002590050297

E. Bombardieri, V. Ambrosini, C. Aktolun, R. Baum, A. Bishof-delaloye et al., 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging, European Journal of Nuclear Medicine and Molecular Imaging, vol.37, issue.3B, pp.1441-1449, 2010.
DOI : 10.1007/s00259-010-1473-6

D. Kwekkeboom, E. Krenning, K. Scheidhauer, V. Lewington, R. Lebtahi et al., ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Somatostatin Receptor Imaging with <sup>111</sup>In-Pentetreotide, Neuroendocrinology, vol.90, issue.2, pp.184-193, 2009.
DOI : 10.1159/000225946

E. Krenning, D. Kwekkeboom, W. Bakker, W. Breeman, P. Kooij et al., Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients, European Journal of Nuclear Medicine, vol.20, issue.8, pp.716-747, 1993.
DOI : 10.1007/BF00181765

W. Breeman, M. De-jong, D. Kwekkeboom, R. Valkema, W. Bakker et al., Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives, European Journal of Nuclear Medicine, vol.28, issue.9, pp.1421-1430, 2001.
DOI : 10.1007/s002590100502

F. Mettler, W. Huda, T. Yoshizumi, and M. M. , Effective Doses in Radiology and Diagnostic Nuclear Medicine: A Catalog, Radiology, vol.248, issue.1, pp.254-63, 2008.
DOI : 10.1148/radiol.2481071451

R. Abgral, S. Leboulleux, D. Déandreis, A. Aupérin, J. Lumbroso et al., Fluorodeoxyglucose-Positron Emission Tomography and Somatostatin Receptor Scintigraphy for High Ki67 (???10%) Well-Differentiated Endocrine Carcinoma Staging, The Journal of Clinical Endocrinology & Metabolism, vol.96, issue.3, pp.665-71, 2011.
DOI : 10.1210/jc.2010-2022

M. Squires, N. Adsay, D. Schuster, M. Russell, K. Cardona et al., Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach, Annals of Surgical Oncology, vol.26, issue.6, pp.1-7, 2015.
DOI : 10.1245/s10434-015-4471-x

I. Kayani, J. Bomanji, A. Groves, G. Conway, S. Gacinovic et al., Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3- octreotate) and 18F-FDG. Cancer, pp.2447-55, 2008.

M. Pavel, E. Baudin, A. Couvelard, E. Krenning, K. Öberg et al., ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary, Neuroendocrinology, vol.95, issue.2, pp.157-76, 2012.
DOI : 10.1159/000335597

T. Binderup, U. Knigge, A. Loft, B. Federspiel, and A. Kjaer, 18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors, Clinical Cancer Research, vol.16, issue.3, pp.978-85, 2010.
DOI : 10.1158/1078-0432.CCR-09-1759

A. Downs, Chemistry of Aluminium, Gallium, Indium, and Thallium, 1993.
DOI : 10.1007/978-94-011-2170-5

H. Maecke and J. André, 68Ga-PET Radiopharmacy: A Generator-Based Alternative to 18F-Radiopharmacy, Ernst Scher Res Found Workshop, issue.62, pp.215-257, 2007.
DOI : 10.1007/978-3-540-49527-7_8

G. Galy and M. Fraysse, Radiopharmacie et médicaments radiopharmaceutiques. [Cachan]: Éd. Tec & doc-Lavoisier, 2012.

C. Morgat, J. Mazère, P. Fernandez, S. Buj, D. Vimont et al., A phantom-based method to standardize dose-calibrators for new ??+-emitters, Nuclear Medicine Communications, vol.36, issue.2, pp.201-207, 2015.
DOI : 10.1097/MNM.0000000000000227

F. Rösch, Past, present and future of 68Ge/68Ga generators, Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. 2013, vol.76, pp.24-30

I. Velikyan, Prospective of 68Ga-Radiopharmaceutical Development. Theranostics, pp.47-80, 2013.

A. Heppeler, S. Froidevaux, H. Mäcke, E. Jermann, M. Béhé et al., Radiometal-Labelled Macrocyclic Chelator-Derivatised Somatostatin Analogue with Superb Tumour-Targeting Properties and Potential for Receptor-Mediated Internal Radiotherapy, Chemistry - A European Journal, vol.5, issue.7, pp.1974-81, 1999.
DOI : 10.1002/(SICI)1521-3765(19990702)5:7<1974::AID-CHEM1974>3.0.CO;2-X

M. Ocak, M. Antretter, R. Knopp, F. Kunkel, M. Petrik et al., Full automation of 68Ga labelling of DOTA-peptides including cation exchange prepurification, Applied Radiation and Isotopes, vol.68, issue.2, 2010.
DOI : 10.1016/j.apradiso.2009.10.006

K. Zhernosekov, D. Filosofov, R. Baum, P. Aschoff, H. Bihl et al., Processing of Generator-Produced 68Ga for Medical Application, Journal of Nuclear Medicine, vol.48, issue.10, pp.1741-1749, 2007.
DOI : 10.2967/jnumed.107.040378

P. Elsinga, S. Todde, I. Penuelas, G. Meyer, B. Farstad et al., Guidance on current good radiopharmacy practice (cGRPP) for the small-scale preparation of radiopharmaceuticals

. Gallium-dota-, Tyr3)-octreotide(68Ga) injection. Pharmeuropa, pp.310-313, 2011.

J. Reubi, J. Schär, B. Waser, S. Wenger, A. Heppeler et al., Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use, European Journal of Nuclear Medicine and Molecular Imaging, vol.27, issue.3, pp.273-82, 2000.
DOI : 10.1007/s002590050034

D. Wild, H. Mäcke, B. Waser, J. Reubi, M. Ginj et al., 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5, European Journal of Nuclear Medicine and Molecular Imaging, vol.28, issue.6, p.724, 2005.
DOI : 10.1007/s00259-004-1697-4

I. Virgolini, V. Ambrosini, J. Bomanji, R. Baum, S. Fanti et al., Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.4, pp.2004-2014, 2010.
DOI : 10.1007/s00259-010-1512-3

U. Eberlein and M. Lassmann, Dosimetry of [ 68 Ga]-labeled compounds, Appl Radiat Isot Data Instrum Methods Use Agric Ind Med. 2013, vol.76, pp.70-74

A. Kroiss, D. Putzer, C. Decristoforo, C. Uprimny, B. Warwitz et al., 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.39, issue.4, pp.514-537
DOI : 10.1007/s00259-012-2309-3

J. Kunikowska, L. Królicki, D. Pawlak, I. Zerizer, and M. Ct, Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTA-TATE PET/CT, Clinical Nuclear Medicine, vol.37, issue.11, pp.1052-1059, 2012.
DOI : 10.1097/RLU.0b013e31825b2555

V. Prasad and R. Baum, Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Radiopharm Chem Biol. Feb, vol.54, issue.1, pp.61-68, 2010.

M. Hofman, W. Lau, and R. Hicks, Ga DOTATATE PET/CT: Clinical Utility, Normal Patterns, Pearls, and Pitfalls in Interpretation, RadioGraphics, vol.35, issue.2, pp.500-516, 2015.
DOI : 10.1148/rg.352140164

V. Froeling, R. Röttgen, F. Collettini, J. Rothe, B. Hamm et al., Detection of pancreatic neuroendocrine tumors (PNET) using semi-quantitative [68Ga]DOTATOC PET in combination with multiphase contrast-enhanced CT, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Radiopharm Chem Biol, vol.58, issue.3, pp.310-318, 2014.

J. Mohandas, R. Kumar, A. Ranganathan, D. Healy, H. Huang et al., Splenunculus Masquerading as a Neuroendocrine Tumor of the Pancreatic Allograft in a Kidney-Pancreas Recipient, Transplantation Journal, vol.96, issue.8, pp.59-62, 2013.
DOI : 10.1097/TP.0b013e3182a80c67

M. Hofmann, H. Maecke, R. Börner, E. Weckesser, P. Schöffski et al., Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data, European Journal of Nuclear Medicine, vol.28, issue.12, pp.1751-1758, 2001.
DOI : 10.1007/s002590100639

I. Buchmann, M. Henze, S. Engelbrecht, M. Eisenhut, A. Runz et al., Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.30, issue.2, pp.1617-1643, 2007.
DOI : 10.1007/s00259-007-0450-1

M. Gabriel, C. Decristoforo, D. Kendler, G. Dobrozemsky, D. Heute et al., 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT, Journal of Nuclear Medicine, vol.48, issue.4, pp.508-526, 2007.
DOI : 10.2967/jnumed.106.035667

D. Putzer, M. Gabriel, B. Henninger, D. Kendler, C. Uprimny et al., Bone Metastases in Patients with Neuroendocrine Tumor: 68Ga-DOTA-Tyr3-Octreotide PET in Comparison to CT and Bone Scintigraphy, Journal of Nuclear Medicine, vol.50, issue.8, 2009.
DOI : 10.2967/jnumed.108.060236

A. Versari, L. Camellini, G. Carlinfante, A. Frasoldati, F. Nicoli et al., Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors, Clinical Nuclear Medicine, vol.35, issue.5, 2010.
DOI : 10.1097/RLU.0b013e3181d6677c

R. Kumar, P. Sharma, P. Garg, S. Karunanithi, N. Naswa et al., Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours, Eur Radiol, 2011.

N. Schreiter, M. Nogami, I. Steffen, U. Pape, B. Hamm et al., Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours, European Radiology, vol.37, issue.Suppl 1, pp.458-67, 2012.
DOI : 10.1007/s00330-011-2266-4

C. Schraml, N. Schwenzer, O. Sperling, P. Aschoff, M. Lichy et al., Staging of neuroendocrine tumours: comparison of [68Ga]DOTATOC multiphase PET/CT and whole-body MRI, Cancer Imaging, vol.13, issue.1, pp.63-72, 2013.
DOI : 10.1102/1470-7330.2013.0007

M. Gabriel, A. Oberauer, G. Dobrozemsky, C. Decristoforo, D. Putzer et al., 68Ga-DOTA-Tyr3-Octreotide PET for Assessing Response to Somatostatin-Receptor-Mediated Radionuclide Therapy, Journal of Nuclear Medicine, vol.50, issue.9, pp.1427-1461, 2009.
DOI : 10.2967/jnumed.108.053421

M. Öksüz, L. Winter, C. Pfannenberg, G. Reischl, K. Müssig et al., Peptide receptor radionuclide therapy of neuroendocrine tumors with 90Y-DOTATOC: Is treatment response predictable by pre-therapeutic uptake of 68Ga-DOTATOC? Diagn Interv Imaging, 2014.

C. Kratochwil, M. Stefanova, E. Mavriopoulou, T. Holland-letz, A. Dimitrakopoulou-strauss et al., SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors, Molecular Imaging and Biology, vol.36, issue.3, pp.1-6, 2014.
DOI : 10.1007/s11307-014-0795-3

I. Velikyan, A. Sundin, J. Sörensen, M. Lubberink, M. Sandström et al., Quantitative and Qualitative Intrapatient Comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: Net Uptake Rate for Accurate Quantification, Journal of Nuclear Medicine, vol.55, issue.2, pp.204-214
DOI : 10.2967/jnumed.113.126177

V. Froeling, F. Elgeti, M. Maurer, C. Scheurig-muenkler, A. Beck et al., Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia, Annals of Nuclear Medicine, vol.5, issue.9, pp.738-781, 2012.
DOI : 10.1007/s12149-012-0634-z

P. Sharma, A. Mukherjee, S. Karunanithi, N. Naswa, R. Kumar et al., Accuracy of 68Ga DOTANOC PET/CT Imaging in Patients With Multiple Endocrine Neoplasia Syndromes, Clinical Nuclear Medicine, vol.40, issue.7, 2015.
DOI : 10.1097/RLU.0000000000000775

S. Sadowski, C. Millo, C. Cottle-delisle, R. Merkel, L. Yang et al., Results of 68Gallium-DOTATATE PET/CT Scanning in Patients with Multiple Endocrine Neoplasia Type 1, Journal of the American College of Surgeons, vol.221, issue.2, pp.509-526, 2015.
DOI : 10.1016/j.jamcollsurg.2015.04.005

N. Schreiter, A. Bartels, V. Froeling, I. Steffen, U. Pape et al., Abstract, Radiology and Oncology, vol.48, issue.4, pp.339-386, 2014.
DOI : 10.2478/raon-2014-0018

Y. Nakamoto, K. Sano, T. Ishimori, M. Ueda, T. Temma et al., Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors, Ann Nucl Med, 2015.

V. Prasad, V. Ambrosini, M. Hommann, D. Hoersch, S. Fanti et al., Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT, European Journal of Nuclear Medicine and Molecular Imaging, vol.35, issue.Suppl 1, pp.67-77, 2010.
DOI : 10.1007/s00259-009-1205-y

A. Kroiss, D. Putzer, A. Frech, C. Decristoforo, C. Uprimny et al., A retrospective comparison between 68Ga-DOTA-TOC PET/CT and 18F-DOPA PET/CT in patients with extra-adrenal paraganglioma, European Journal of Nuclear Medicine and Molecular Imaging, vol.54, issue.12, pp.1800-1808, 2013.
DOI : 10.1007/s00259-013-2548-y

A. Kroiss, B. Shulkin, C. Uprimny, A. Frech, R. Gasser et al., Ga-DOTATOC PET/CT provides accurate tumour extent in patients with extraadrenal paraganglioma compared to (123)I-MIBG SPECT/CT, Eur J Nucl Med Mol Imaging. 2015, vol.6842, issue.1, pp.33-41

Z. Win, A. Nahhas, D. Towey, J. Todd, D. Rubello et al., 68Ga-DOTATATE PET in neuroectodermal tumours: First experience, Nuclear Medicine Communications, vol.28, issue.5, pp.359-63, 2007.
DOI : 10.1097/MNM.0b013e32808ea0b0

A. Afshar-oromieh, F. Giesel, H. Linhart, U. Haberkorn, S. Haufe et al., Detection of cranial meningiomas: comparison of 68Ga-DOTATOC PET/CT and contrast-enhanced MRI, European Journal of Nuclear Medicine and Molecular Imaging, vol.47, issue.1, pp.1409-1424, 2012.
DOI : 10.1007/s00259-012-2155-3

R. Graf, F. Nyuyki, I. Steffen, R. Michel, D. Fahdt et al., Contribution of 68Ga-DOTATOC PET/CT to Target Volume Delineation of Skull Base Meningiomas Treated With Stereotactic Radiation Therapy, International Journal of Radiation Oncology*Biology*Physics, vol.85, issue.1, pp.68-73, 2013.
DOI : 10.1016/j.ijrobp.2012.03.021

L. Lambert, S. Shapiro, J. Lee, N. Perrier, M. Truong et al., Surgical Treatment of Hyperparathyroidism in Patients With Multiple Endocrine Neoplasia Type 1, Archives of Surgery, vol.140, issue.4, pp.374-82, 1960.
DOI : 10.1001/archsurg.140.4.374

N. Nilubol, L. Weinstein, W. Simonds, R. Jensen, G. Phan et al., Preoperative Localizing Studies for Initial Parathyroidectomy in MEN1 Syndrome: Is There Any Benefit?, World Journal of Surgery, vol.32, issue.6, pp.1368-74
DOI : 10.1007/s00268-012-1451-1

N. Launay, S. Silvera, F. Tenenbaum, L. Groussin, F. Tissier et al., Value of 18-F-FDG PET/CT and CT in the Diagnosis of Indeterminate Adrenal Masses, International Journal of Endocrinology, vol.10, p.213875, 2015.
DOI : 10.2214/ajr.08.1431

C. Chen and J. Carrasquillo, Molecular imaging of adrenal neoplasms, Journal of Surgical Oncology, vol.22, issue.5, pp.532-574, 2012.
DOI : 10.1002/jso.23162

A. Dong, Y. Cui, Y. Wang, C. Zuo, and Y. Bai, F-FDG PET/CT of Adrenal Lesions, American Journal of Roentgenology, vol.203, issue.2, pp.245-52, 2014.
DOI : 10.2214/AJR.13.11793

M. Nocaudie-calzada, D. Huglo, M. Lambert, O. Ernst, C. Proye et al., Efficacy of iodine-131 6beta-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism, Eur J Nucl Med, vol.26, issue.10, pp.1326-1358, 1999.

D. Taïeb, H. Neumann, D. Rubello, A. Nahhas, B. Guillet et al., Modern Nuclear Imaging for Paragangliomas: Beyond SPECT, Journal of Nuclear Medicine, vol.53, issue.2, pp.264-74
DOI : 10.2967/jnumed.111.098152

D. Taïeb, H. Timmers, E. Hindié, B. Guillet, H. Neumann et al., EANM 2012 guidelines for radionuclide imaging of phaeochromocytoma and paraganglioma, European Journal of Nuclear Medicine and Molecular Imaging, vol.72, issue.Suppl 1, pp.1977-95, 2012.
DOI : 10.1007/s00259-012-2215-8

M. Falconi, D. Bartsch, B. Eriksson, G. Klöppel, J. Lopes et al., ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors, Neuroendocrinology, vol.95, issue.2, pp.120-154, 2012.
DOI : 10.1159/000335587

J. Yao, M. Shah, T. Ito, C. Bohas, E. Wolin et al., Everolimus for Advanced Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.514-537, 2011.
DOI : 10.1056/NEJMoa1009290

E. Raymond, L. Dahan, R. J. Bang, Y. Borbath, I. Lombard-bohas et al., Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors, New England Journal of Medicine, vol.364, issue.6, pp.501-514, 2011.
DOI : 10.1056/NEJMoa1003825

B. Kos-kud?a, O. Toole, D. Falconi, M. Gross, D. Klöppel et al., ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors, Neuroendocrinology, vol.91, issue.4, pp.341-50, 2010.
DOI : 10.1159/000287255

H. Ahlman, O. Nilsson, A. Mcnicol, P. Ruszniewski, B. Niederle et al., Poorly-Differentiated Endocrine Carcinomas of Midgut and Hindgut Origin, Neuroendocrinology, vol.87, issue.1, pp.40-46, 2008.
DOI : 10.1159/000109976

J. Zaknun, L. Bodei, J. Mueller-brand, M. Pavel, R. Baum et al., The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.20, issue.Suppl 1, pp.800-816, 2013.
DOI : 10.1007/s00259-012-2330-6

A. Imhof, P. Brunner, N. Marincek, M. Briel, C. Schindler et al., Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers, Journal of Clinical Oncology, vol.29, issue.17, pp.2416-2439, 2011.
DOI : 10.1200/JCO.2010.33.7873

J. Teunissen, D. Kwekkeboom, R. Valkema, and E. Krenning, Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours, Endocrine Related Cancer, vol.18, issue.S1, pp.27-51, 2011.
DOI : 10.1530/ERC-10-0282

D. Kwekkeboom, W. Herder, . De, B. Kam, C. Eijck et al., ]Octreotate: Toxicity, Efficacy, and Survival, Journal of Clinical Oncology, vol.26, issue.13, pp.2124-2154, 2008.
DOI : 10.1200/JCO.2007.15.2553

D. Kwekkeboom, E. Krenning, R. Lebtahi, P. Komminoth, B. Kos-kud?a et al., ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogs, Neuroendocrinology, vol.90, issue.2, pp.220-226, 2009.
DOI : 10.1159/000225951

M. Fani, J. André, and H. Maecke, 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals, Contrast Media & Molecular Imaging, vol.22, issue.2, pp.53-63, 2008.
DOI : 10.1002/cmmi.232

I. Velikyan, G. Beyer, and B. Långström, Ga Bioconjugates with High Specific Radioactivity, Bioconjugate Chemistry, vol.15, issue.3, pp.554-60, 2004.
DOI : 10.1021/bc030078f

I. Velikyan, H. Xu, M. Nair, H. Hall, and D. Dota-toc, Robust labeling and comparative preclinical characterization of DOTA-TOC and DOTA-TATE, Nuclear Medicine and Biology, vol.39, issue.5, pp.628-667
DOI : 10.1016/j.nucmedbio.2011.12.010

J. Kowalski, M. Henze, J. Schuhmacher, H. Mäcke, M. Hofmann et al., Evaluation of Positron Emission Tomography Imaging Using [68Ga]-DOTA-D Phe1-Tyr3-Octreotide in Comparison to [111In]-DTPAOC SPECT. First Results in Patients with Neuroendocrine Tumors, Molecular Imaging & Biology, vol.5, issue.1, pp.42-50, 2003.
DOI : 10.1016/S1536-1632(03)00038-6

S. Van-binnebeek, B. Vanbilloen, K. Baete, C. Terwinghe, M. Koole et al., Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours, Eur Radiol, 2015.

H. Jacobsson, P. Larsson, C. Jonsson, E. Jussing, and P. Grybäck, Normal Uptake of 68Ga-DOTA-TOC by the Pancreas Uncinate Process Mimicking Malignancy at Somatostatin Receptor PET, Clinical Nuclear Medicine, vol.37, issue.4, pp.362-367
DOI : 10.1097/RLU.0b013e3182485110

J. Bunning, S. Merchant, L. Crooks, and M. Hartshorne, Indium-111 Pentetreotide Uptake By Pancreatic Polypeptide Cell Hyperplasia, Pancreas, vol.35, issue.4, pp.372-377, 2007.
DOI : 10.1097/mpa.0b013e31811ea2a2

V. Froeling, F. Elgeti, M. Maurer, C. Scheurig-muenkler, A. Beck et al., Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia, Annals of Nuclear Medicine, vol.5, issue.9, pp.738-781, 2012.
DOI : 10.1007/s12149-012-0634-z

P. Sharma, S. Arora, S. Karunanithi, R. Khadgawat, P. Durgapal et al., Somatostatin receptor based PET/CT imaging with 68Ga-DOTA-Nal3-Octreotide for localisation of clinically and biochemically suspected insulinoma, Q J Nucl Med Mol Imaging Off Publ Ital Assoc Nucl Med AIMN Int Assoc Radiopharmacol IAR Sect Soc Of, 2014.

A. Imperiale, F. Sebag, M. Vix, F. Castinetti, L. Kessler et al., 18F-FDOPA PET/CT imaging of insulinoma revisited, European Journal of Nuclear Medicine and Molecular Imaging, vol.33, issue.3, pp.409-427
DOI : 10.1007/s00259-014-2943-z

J. Reubi, Peptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy, Endocrine Reviews, vol.24, issue.4, pp.389-427, 2003.
DOI : 10.1210/er.2002-0007

K. Antwi, M. Fani, G. Nicolas, C. Rottenburger, T. Heye et al., Localization of Hidden Insulinomas with 68Ga-DOTA-Exendin-4 PET/CT: A Pilot Study, Journal of Nuclear Medicine, vol.56, issue.7, 2015.
DOI : 10.2967/jnumed.115.157768

E. Hindié, Ö. Ugur, D. Fuster, M. Odoherty, G. Grassetto et al., 2009 EANM parathyroid guidelines, EANM parathyroid guidelines, pp.1201-1217, 2009.
DOI : 10.1007/s00259-009-1131-z

T. Ishizuka, K. Kajita, K. Kamikubo, T. Komaki, K. Miura et al., Phospholipid/Ca2+-dependent Protein Kinase Activity in Human Parathyroid Adenoma., Endocrinologia Japonica, vol.34, issue.6, 1987.
DOI : 10.1507/endocrj1954.34.965

L. Lezaic, S. Rep, M. Sever, T. Kocjan, M. Hocevar et al., 18F-Fluorocholine PET/CT for localization of hyperfunctioning parathyroid tissue in primary hyperparathyroidism: a pilot study, European Journal of Nuclear Medicine and Molecular Imaging, vol.248, issue.6, pp.2083-2092, 2014.
DOI : 10.1007/s00259-014-2837-0

M. Mayerhoefer, M. Schuetz, S. Magnaldi, M. Weber, S. Trattnig et al., Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?, European Radiology, vol.37, issue.4, pp.938-984
DOI : 10.1007/s00330-011-2328-7

N. Schreiter, M. Maurer, U. Pape, B. Hamm, W. Brenner et al., Detection of neuroendocrine tumours in the small intestines using contrast-enhanced multiphase Ga-68 DOTATOC PET/CT: the potential role of arterial hyperperfusion, Radiology and Oncology, vol.48, issue.2, pp.120-126, 2014.
DOI : 10.2478/raon-2014-0012

J. Ruf, J. Schiefer, C. Furth, O. Kosiek, S. Kropf et al., 68Ga-DOTATOC PET/CT of Neuroendocrine Tumors: Spotlight on the CT Phases of a Triple-Phase Protocol, Journal of Nuclear Medicine, vol.52, issue.5, pp.697-704, 2011.
DOI : 10.2967/jnumed.110.083741

C. Touzery, A. B. Caselles, O. Gardin, I. Guilhem, M. Laffont et al., Dosimétrie des explorations diagnostiques en médecine nucléaire. SFPM, pp.19-2001, 2001.

N. Schreiter, W. Brenner, M. Nogami, R. Buchert, A. Huppertz et al., Cost comparison of 111In-DTPA-octreotide scintigraphy and 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours, European Journal of Nuclear Medicine and Molecular Imaging, vol.13, issue.3, pp.72-82
DOI : 10.1007/s00259-011-1935-5

A. Frilling, G. Sotiropoulos, A. Radtke, M. Malago, A. Bockisch et al., The Impact of 68Ga-DOTATOC Positron Emission Tomography/Computed Tomography on the Multimodal Management of Patients With Neuroendocrine Tumors, Annals of Surgery, vol.252, issue.5, pp.850-856, 2010.
DOI : 10.1097/SLA.0b013e3181fd37e8

C. Johnbeck, U. Knigge, and A. Kjaer, PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature, Future Oncology, vol.10, issue.14, pp.2259-77, 2014.
DOI : 10.2217/fon.14.139

A. Pfeifer, U. Knigge, T. Binderup, J. Mortensen, P. Oturai et al., 64Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with 111In-DTPA-Octreotide in 112 Patients, Journal of Nuclear Medicine, vol.56, issue.6, pp.847-54, 2015.
DOI : 10.2967/jnumed.115.156539

G. Meisetschläger, T. Poethko, A. Stahl, I. Wolf, K. Scheidhauer et al., Gluc- Lys([18F]FP)-TOCA PET in patients with SSTR-positive tumors: biodistribution and diagnostic evaluation compared with [111In]DTPA-octreotide, 2006.

F. Montravers, D. Grahek, K. Kerrou, P. Ruszniewski, V. Beco et al., Can Fluorodihydroxyphenylalanine PET Replace Somatostatin Receptor Scintigraphy in Patients with Digestive Endocrine Tumors?, J Nucl Med, vol.47, issue.9, pp.1455-62, 2006.

F. Montravers, K. Kerrou, V. Nataf, V. Huchet, J. Lotz et al., Impact of Fluorodihydroxyphenylalanine-(18F) Positron Emission Tomography on Management of Adult Patients with Documented or Occult Digestive Endocrine Tumors, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.4, 2009.
DOI : 10.1210/jc.2008-1349